Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 1,301–1,400 of 12,156

  1. Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship
    Peter J. Little, Christopher David Askew, Suowen Xu, Danielle Kamato · 2021 · Biomedicines
  2. Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
    Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik · 2022 · International Journal of Molecular Sciences
  3. Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023
    José Antônio Marin‐Neto, Anis Rassi, Gláucia Maria Moraes de Oliveira, Luís Cláudio Lemos Correia, Alberto Novaes Ramos, Alejandro O. Luquetti, Alejandro Marcel Hasslocher‐Moreno, Andréa Silvestre de Sousa, Ângelo Amato Vincenzo de Paola, Antônio Carlos Sobral Sousa et al. · 2023 · Arquivos Brasileiros de Cardiologia
  4. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
    Rhona Johnston, Olalekan Abdulrahman Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill L Colquitt, Bee Kang Tan, Andrew J Clegg, Saran Shantikumar, Rachel A. Court et al. · 2017 · Health Technology Assessment
  5. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways
    Joubert, M., Manrique, A., Cariou, B., Prieur, X. · 2019 · Diabetes & Metabolism
  6. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist · 2022 · Frontiers in Endocrinology
  7. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · Diabetologia
  8. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
    Irace, Concetta, Casciaro, Francesco, Scavelli, Faustina Barbara, Oliverio, Rosa, Cutruzzolà, Antonio, Cortese, Claudio, Gnasso, Agostino · 2018 · Cardiovascular Diabetology
  9. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V
    Ferrannini, Giulia, De Bacquer, Dirk, De Backer, Guy, Kotseva, Kornelia, Mellbin, Linda, Wood, David, Rydén, Lars, EUROASPIRE V collaborators, Gale, Christopher P., Beleslin, Branko et al. · 2020 · Diabetes Care
  10. <scp>Sodium‐glucose co‐transporter‐2</scp> inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
    Neuen, Brendon L., Arnott, Clare, Perkovic, Vlado, Figtree, Gemma, de Zeeuw, Dick, Fulcher, Greg, Jun, Min, Jardine, Meg J., Zoungas, Sophia, Pollock, Carol et al. · 2021 · Diabetes, Obesity and Metabolism
  11. Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus
    Atsunori Kashiwagi, Hiroshi Maegawa · 2017 · Journal of Diabetes Investigation
  12. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
    Zien Zhou, Meg Jardine, Vlado Perkovic, David Richard Matthews, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul G. Desai, Richard Oh, Roger Simpson et al. · 2019 · Diabetologia
  13. The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases
    Saltanat Zhazykbayeva, Steffen Pabel, Andreas Mügge, Samuel Tobias Sossalla, Nazha Hamdani · 2020 · Biophysical Reviews
  14. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
    Semlitsch, Thomas, Engler, Jennifer, Siebenhofer, Andrea, Jeitler, Klaus, Berghold, Andrea, Horvath, Karl · 2020 · Cochrane Database of Systematic Reviews
  15. Towards precision medicine in heart failure
    Chad S. Weldy, Euan Angus Ashley · 2021 · Nature Reviews Cardiology
  16. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Rujie Zheng, Yue Wang, Junnan Tang, Jie-Ying Duan, Ming-Yue Yuan, Jinying Zhang · 2022 · PubMed Central
  17. Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β‐cell function and reduction of insulin resistance
    Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Seizo Okauchi, Naoki Shimo, Taka‐aki Matsuoka, Kohei Kaku · 2016 · Journal of Diabetes
  18. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
    Ilaria Dicembrini, Besmir Nreu, Alessia Scatena, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2017 · Acta Diabetologica
  19. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health
    Ahmad Moolla, Kenzo Motohashi, Thomas Marjot, Amelia Shard, Mark Andrew Ainsworth, Alastair McIntosh Gray, Rury R. Holman, Michael Pavlides, John Denis Ryan, Jeremy Tomlinson et al. · 2019 · Frontline Gastroenterology
  20. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
    Huilin Tang, Dandan Li, Tiansheng Wang, Suodi Zhai, Yiqing Song · 2016 · Diabetes Care
  21. Heart failure with preserved ejection fraction: current management and future strategies
    Carsten Tschöpe, Christoph M. Birner, Michael Böhm, Oliver Bruder, Stefan Frantz, Andreas Luchner, Lars Siegfried Maier, Stefan Störk, Behrouz Kherad, Ulrich Laufs · 2017 · Clinical Research in Cardiology
  22. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
    Yuya Seko, Taichiro Nishikawa, Atsushi Umemura, Kanji Yamaguchi, Michihisa Moriguchi, Kohichiroh Yasui, Mayumi Kimura, Hiroaki Iijima, Toshio Hashimoto, Yoshio Sumida et al. · 2018 · Diabetes Metabolic Syndrome and Obesity
  23. Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation
    Revathy Carnagarin, Márcio Galindo Kiuchi, Jan K. Ho, Vance Bruce Matthews, Markus Peter Schlaich · 2019 · Frontiers in Neuroscience
  24. The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
    Dhiren K Patel, Jodi L. Strong · 2019 · Diabetes Therapy
  25. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
    Shih‐Chieh Shao, Kai‐Cheng Chang, Ming‐Jui Hung, Ning-I Yang, Yuk‐Ying Chan, Hui‐Yu Chen, Yea‐Huei Kao Yang, Edward Chia‐Cheng Lai · 2019 · Cardiovascular Diabetology
  26. Oral semaglutide in type 2 diabetes
    Sarah L. Anderson, Trevor R. Beutel, Jennifer M. Trujillo · 2020 · Journal of Diabetes and its Complications
  27. Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients
    Fatima AlKindi, Hanan Luay Al-Omary, Qutaiba Hussain, Mohamed Al Hakim, Ahmed Chaaban, Yousef Abdul Rahim Boobes · 2020 · Transplantation Proceedings
  28. Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms
    Olurotimi O. Mesubi, Adam G. Rokita, Neha Abrol, Yuejin Wu, Biyi Chen, Qinchuan Wang, Jonathan M. Granger, Anthony Tucker-Bartley, Elizabeth D. Luczak, Kevin R. Murphy et al. · 2020 · Journal of Clinical Investigation
  29. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
    Alexandros Kasiakogias, Enrico Agabiti Rosei, Miguel Camafort, Georg Ehret, Luca Faconti, João Pedro Ferreira, Jana Brguljan-Hitij, Andrzej Januszewicz, Thomas Kahan, Athanasios John Manolis et al. · 2021 · Journal of Hypertension
  30. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
    Adam J. Nelson, Neha Jadeja Pagidipati, Vanita R. Aroda, Matthew Aaron Cavender, Jennifer B. Green, Renato D. Lópes, Hussein R. Al‐Khalidi, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk et al. · 2021 · Circulation
  31. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
    Min Zhuo, Julie M. Paik, Deborah J. Wexler, Joseph Vincent Bonventre, Seoyoung C. Kim, Elisabetta Patorno · 2021 · American Journal of Kidney Diseases
  32. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
    Frank L.J. Visseren, François Mach, Yvo Michiel Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Bénétos, Alessandro Biffi, José Manuel Boavida, Davide Capodanno et al. · 2022 · Revista Española de Cardiología
  33. <scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp> ‐2α signaling pathway in arrhythmogenic cardiomyopathy
    Yang, Zhe, Li, Tengling, Xian, Jianzhong, Chen, Jia, Huang, Yin, Zhang, Qin, Lin, Xiufang, Lu, Hongyun, Lin, Yubi · 2022 · The FASEB Journal
  34. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease
    Heng‐Chih Pan, Jui‐Yi Chen, Hsing‐Yu Chen, Fang-Yu Yeh, Thomas Tao-Min Huang, Chiao‐Yin Sun, Shiow‐Ing Wang, James Cheng‐Chung Wei, Vin‐Cent Wu · 2024 · JAMA Network Open
  35. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
    Mary Eugenia Rinella, James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Stephen A. Harrison · 2018 · Journal of Hepatology
  36. Monocytes and macrophages as protagonists in vascular complications of diabetes
    Kanter, Jenny E., Hsu, Cheng-Chieh, Bornfeldt, Karin E. · 2020 · Frontiers in Cardiovascular Medicine
  37. Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial
    Sharma, Abhinav, Green, Jennifer B., Dunning, Allison, Lokhnygina, Yuliya, Al-Khatib, Sana M., Lopes, Renato D., Buse, John B., Lachin, John M., Van de Werf, Frans, Armstrong, Paul W. et al. · 2017 · Diabetes Care
  38. External validity, generalisability, applicability and directness: a brief primer
    Murad, Mohammad H, Katabi, Abdulrahman, Benkhadra, Raed, Montori, Victor M · 2018 · BMJ Evidence-Based Medicine
  39. Targeting inflammation in diabetic kidney disease: early clinical trials
    María Vanessa Pérez-Gómez, María Dolores Sánchez-Niño, Ana Belen Sanz, Binbin Zheng-Lin, Catalina Martín-Cleary, Marta Ruiz‐Ortega, Alberto Ortíz, Beatriz Fernández‐Fernández · 2016 · Expert Opinion on Investigational Drugs
  40. SGLT2 inhibitors in the management of type 2 diabetes
    R. P. Monica Reddy, Silvio E. Inzucchi · 2016 · Endocrine
  41. Roles of Perivascular Adipose Tissue in the Pathogenesis of Atherosclerosis
    Kimie Tanaka, Masataka Sata · 2018 · Frontiers in Physiology
  42. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017
    Helen J Curtis, John Dennis, Beverley M. Shields, Alex J Walker, Seb Bacon, Andrew Tym Hattersley, Angus G. Jones, Ben M. Goldacre · 2018 · Diabetes Obesity and Metabolism
  43. Clinical management of type 2 diabetes in south Asia
    Anoop Misra, Naveed A. Sattar, Nikhil Tandon, Usha Shrivastava, Naval K. Vikram, Kamlesh K. Khunti, Andrew Peter Hills · 2018 · The Lancet Diabetes & Endocrinology
  44. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
    Toshinobu MAKI, Sayaka Maeno, Yasutaka Maeda, Mayumi Yamato, Noriyuki Sonoda, Yoshihiro Ogawa, Masanori Wakisaka, Toyoshi Inoguchi · 2019 · Scientific Reports
  45. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
    Yumin Gao, Eric David Peterson, Neha Jadeja Pagidipati · 2020 · American Heart Journal
  46. Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
    Rio P. Juni, Rushd Al‐Shama, Diederik W.D. Kuster, Jolanda van der Velden, Henrike M. Hamer, Marc G. Vervloet, Etto C. Eringa, Pieter Koolwijk, Victor W.M. van Hinsbergh · 2020 · Kidney International
  47. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
    Dan Atar, J. Wouter Jukema, Bart Molemans, Pam R. Taub, Shinya Goto, François Mach, Cesar Cerezo Olmos, James A. Underberg, ANTHONY C. KEECH, Lale S Tokgözoğlu et al. · 2021 · Atherosclerosis
  48. Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Nelson, Adam J., O’Brien, Emily C., Kaltenbach, Lisa A., Green, Jennifer B., Lopes, Renato D., Morse, Caryn G., Al-Khalidi, Hussein R., Aroda, Vanita R., Cavender, Matthew A., Gaynor, Tanya et al. · 2022 · JAMA Network Open
  49. A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
    Michelle Maya Kittleson · 2022 · Journal of Cardiac Failure
  50. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
    Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, James R. Sowers, Wenshuo Wang, Junbo Ge, Jun Tao Ren, Yingmei Zhang · 2022 · Journal of Molecular Cell Biology
  51. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation
    Hideyuki Kishima, Takanao Mine, Eiji Fukuhara, Ryo Kitagaki, Masanori Asakura, Masaharu Ishihara · 2022 · JACC. Clinical electrophysiology
  52. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
    Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, Pier Francesco Rambaldi, Carlo Fumagalli, Ludovica Vittoria Marfella, Rosalba La Grotta, Chiara Frigé, Valeria Pellegrini, Davide D’Andrea et al. · 2024 · Cardiovascular Diabetology
  53. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
    Abdul Waheed Khan, Karin Agnes Maria Jandeleit-Dahm · 2025 · Nature Reviews Cardiology
  54. An update on DPP-4 inhibitors in the management of type 2 diabetes
    Avivit Cahn, Simona Cernea, Itamar Raz · 2016 · Expert Opinion on Emerging Drugs
  55. Therapeutic medications against diabetes: What we have and what we expect
    Cheng Hu, Weiping Jia · 2018 · Advanced Drug Delivery Reviews
  56. Cardiovascular outcome trials in obesity: A review
    Wilding, John P.H., Jacob, Stephan · 2021 · Obesity Reviews
  57. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
    Garg, Satish K., Kaur, Gurleen, Haider, Zehra, Rodriquez, Erika, Beatson, Christie, Snell-Bergeon, Janet · 2024 · Diabetes Technology &amp; Therapeutics
  58. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2021 · Cardiovascular Diabetology
  59. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó, Rafael, Hernández, Cristina · 2017 · Diabetes
  60. Understanding EMPA-REG OUTCOME
    Marcel H.A. Muskiet, Daniël H. van Raalte, Erik J.M. van Bommel, Mark M. Smits, Lennart Tonneijck · 2015 · The Lancet Diabetes & Endocrinology
  61. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
    Muhammad A Abdul‐Ghani, Amin Jayyousi, Ralph A. DeFronzo, Nidal Asaad, Jassim M. S. Al Suwaidi · 2017 · Current Vascular Pharmacology
  62. Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
    Patrick Meagher, Mohamed Adam, Robert Civitarese, Antoinette Bugyei‐Twum, Kim Alexander Connelly · 2018 · Canadian Journal of Cardiology
  63. Worsening Heart Failure During the Use of DPP-4 Inhibitors
    Milton Packer · 2018 · JACC Heart Failure
  64. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
    Chih‐Chao Yang, Yen-Ta Chen, Christopher Glenn Wallace, Kuan‐Hung Chen, Ben‐Chung Cheng, Pei‐Hsun Sung, Yi‐Chen Li, Sheung‐Fat Ko, Hsueh‐Wen Chang, Hon‐Kan Yip · 2018 · Biomedicine & Pharmacotherapy
  65. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME ® trial
    Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka‐Weber · 2018 · Journal of Diabetes Investigation
  66. Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
    Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J.L. Heerspink · 2020 · Journal of the American Heart Association
  67. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
    Vincenzo Quagliariello, Michelino De Laurentiis, Stefania Cocco, Giuseppina Rea, Annamaria Bonelli, Antonietta Caronna, Maria Cristina Lombari, Gabriele Conforti, Massimiliano Berretta, Gerardo Botti et al. · 2020 · International Journal of Molecular Sciences
  68. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
    Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro · 2021 · Cardiovascular Diabetology
  69. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats
    Scott Culver Thomson, Volker Vallon · 2021 · American Journal of Physiology-Renal Physiology
  70. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
    Nan Zhang, Yueying Wang, Gary Tse, Panagiotis G. Korantzopoulos, Κonstantinos P. Letsas, Qingpeng Zhang, Guangping Li, Gregory Y.H. Lip, Tong Liu · 2021 · European Journal of Preventive Cardiology
  71. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
    Peter R Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F. Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr P. Ponikowski et al. · 2021 · The Lancet Diabetes & Endocrinology
  72. The Kidney Failure Risk Equation: Evaluation of Novel Input Variables including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts
    Morgan Erika Grams, Nigel John Brunskill, Shoshana H. Ballew, Yingying Sang, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Samira Bell, Juan Jesús Carrero, Gabriel Chodick et al. · 2023 · Journal of the American Society of Nephrology
  73. Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis
    Wen Zhou, Petra Šimić, Iris Yuwen Zhou, Peter D. Caravan, Xavier Fernando Vela Parada, Donghai Wen, Onica L. Washington, Maria Shvedova, Kerry A. Pierce, Clary B. Clish et al. · 2023 · Journal of Clinical Investigation
  74. Ketones and the cardiovascular system
    Gary D. Lopaschuk, Jason R.B. Dyck · 2023 · Nature Cardiovascular Research
  75. Cardiovascular Disease in Diabetes and Chronic Kidney Disease
    Sowmya Swamy, Sahibzadi Mahrukh Noor, Roy O. Mathew · 2023 · Journal of Clinical Medicine
  76. Contemporary pharmacological treatment and management of heart failure
    Biykem Bozkurt · 2024 · Nature Reviews Cardiology
  77. Glucagon and heart in type 2 diabetes: new perspectives
    Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda · 2016 · Cardiovascular Diabetology
  78. Telemedicine in Primary Care for Patients With Chronic Conditions: The ValCrònic Quasi-Experimental Study
    Domingo Orozco‐Beltrán, Manuel Sánchez-Molla, Julio Jesús Sánchez García, José Joaquín Mira · 2017 · Journal of Medical Internet Research
  79. Histone Deacetylase Inhibitors and Diabetic Kidney Disease
    Mitchell J. Hadden, Andrew Advani · 2018 · International Journal of Molecular Sciences
  80. Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production
    Jakob Grunnet Knudsen, Alexander Hamilton, Reshma D. Ramracheya, Andrei I. Tarasov, Melissa F. Brereton, Elizabeth Haythorne, Margarita V. Chibalina, Peter Spégel, Hindrik Mulder, Quan Zhang et al. · 2018 · Cell Metabolism
  81. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
    Sfairopoulos, Dimitrios, Zhang, Nan, Wang, Yueying, Chen, Ziliang, Letsas, Konstantinos P, Tse, Gary, Li, Guangping, Lip, Gregory Y H, Liu, Tong, Korantzopoulos, Panagiotis · 2022 · EP Europace
  82. Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
    Al-Salameh, Abdallah, Chanson, Philippe, Bucher, Sophie, Ringa, Virginie, Becquemont, Laurent · 2019 · Mayo Clinic Proceedings
  83. Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
    Hana E. Baker, Alexander M Kiel, Samuel T Luebbe, Blake R. Simon, Conner C. Earl, Ajit Regmi, William C. Roell, Kieren J. Mather, Johnathan D. Tune, Adam Glenn Goodwill · 2019 · Basic Research in Cardiology
  84. Substantial and Sustained Improvements in Blood Pressure, Weight and Lipid Profiles from a Carbohydrate Restricted Diet: An Observational Study of Insulin Resistant Patients in Primary Care
    David J. Unwin, Simon Tobin, Scott W. Murray, Christine Delon, Adrian J B Brady · 2019 · International Journal of Environmental Research and Public Health
  85. Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study
    Carina Iskander, David Z.I. Cherney, Kristin K. Clemens, Stephanie N. Dixon, Ziv Harel, Nivethika Jeyakumar, Eric McArthur, Flory Tsobo Muanda, Chirag R. Parikh, John Michael Paterson et al. · 2020 · Canadian Medical Association Journal
  86. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
    Qutuba G. Karwi, Kim L. Ho, Simran Pherwani, Ezra B. Ketema, Qiuyu Sun, Gary D. Lopaschuk · 2021 · Cardiovascular Research
  87. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
    Michael J. Szarek, Deepak L. Bhatt, Philippe Gabríel Steg, Christopher Paul Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia Breyer Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra et al. · 2021 · Annals of Internal Medicine
  88. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
    Josephine Harrington, Jacob Allen Udell, W. Schuyler Jones, Stefan D. Anker, Deepak L. Bhatt, Mark Colquhoun Petrie, Ola Vedin, Mikhail Sumin, Isabella Zwiener, Adrian F. Hernandez et al. · 2022 · American Heart Journal
  89. Predicting and preventing heart failure in type 2 diabetes
    Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, Deepak L. Bhatt, Subodh Verma · 2023 · The Lancet Diabetes & Endocrinology
  90. Advances in the management of type 2 diabetes in adults
    Rodolfo Javier Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, Rozalina G. McCoy · 2023 · BMJ Medicine
  91. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
    Franco Arturi, Elena Succurro, Sofia Miceli, Cosima Cloro, Mariafrancesca Ruffo, Raffaele Maio, Maria Perticone, Giorgio Sesti, Francesco Perticone · 2016 · Endocrine
  92. Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
    Ghadeer K. Dawwas, Steven M. Smith, Haesuk Park · 2018 · Diabetes Obesity and Metabolism
  93. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress
    Panagiota Nikolaou, Panagiotis Efentakis, Fairouz Abu Qourah, Saveria Femminò, Manousos Makridakis, Zoi Kanaki, Aimilia Varela, Maria E. Tsoumani, Constantinos H. Davos, Constantinos A. Dimitriou et al. · 2020 · Antioxidants and Redox Signaling
  94. Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
    Yasui, Atsutaka, Lee, Ganghyuck, Hirase, Tetsuaki, Kaneko, Tatsuroh, Kaspers, Stefan, von Eynatten, Maximilian, Okamura, Tomoo · 2018 · Diabetes Therapy
  95. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
    Staplin, Natalie, Roddick, Alistair J., Emberson, Jonathan, Reith, Christina, Riding, Alex, Wonnacott, Alexa, Kuverji, Apexa, Bhandari, Sunil, Baigent, Colin, Haynes, Richard et al. · 2021 · eClinicalMedicine
  96. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    Xingjuan Shi, Subodh Verma, Junghwa Yun, Koroboshka Brand‐Arzamendi, Krishna Kumar Singh, Xiangdong Liu, Ankit Garg, Adrian Quan, Xiao‐Yan Wen · 2017 · Molecular and Cellular Biochemistry
  97. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
    Hadi Fattah, Volker Vallon · 2018 · Drugs
  98. Diabetes Mellitus Secondary to Cushing’s Disease
    Mattia Barbot, Filippo Ceccato, Carla Maria Scaroni · 2018 · Frontiers in Endocrinology
  99. Ketone metabolism in the failing heart
    Gary D. Lopaschuk, Qutuba G. Karwi, Kim L. Ho, Simran Pherwani, Ezra B. Ketema · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  100. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA
    HoJin Shin, Sebastian Schneeweiß, Robert J. Glynn, Elisabetta Patorno · 2021 · Diabetes Care